Iain D. Dukes

CIK: 0001681955

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)7 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (3)

TRAW

Traws Pharma, Inc.

DirectorOfficer

IOVA

IOVANCE BIOTHERAPEUTICS, INC.

Director

NONE

Lomond Therapeutics Holdings, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (7 total)

TRAW
Traws Pharma, Inc.
Jul 9, 2026
Award(A)
Stock Option (right to buy)
Direct
274K shares-
IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Jun 16, 2026
Award(A)
Deferred Restricted Stock Unit
Direct
180.6K shares-
TRAW
Traws Pharma, Inc.
Mar 8, 2026
Award(A)
Stock Option (right to buy)
Direct
231.3K shares-
TRAW
Traws Pharma, Inc.
Dec 12, 2025
Award(A)
Direct
36.9K shares-
TRAW
Traws Pharma, Inc.
Oct 12, 2025
Award(A)
Stock Option (right to purchase)
Direct
64.8K shares-
IOVA
IOVANCE BIOTHERAPEUTICS, INC.
Jun 13, 2025
Award(A)
Deferred Restricted Stock Unit
Direct
135.1K shares-
No ticker
Lomond Therapeutics Holdings, Inc.
Nov 1, 2024
Award(A)
Stock Option (Right to Buy)
Direct
2.1M shares-

		Type	Shares	Price		Ownership
Jul 9, 2026	TRAW Traws Pharma, Inc.	Award(A) Stock Option (right to buy)	274,000	-	-	Direct
Jun 16, 2026	IOVA IOVANCE BIOTHERAPEUTICS, INC.	Award(A) Deferred Restricted Stock Unit	180,632	-	-	Direct
Mar 8, 2026	TRAW Traws Pharma, Inc.	Award(A) Stock Option (right to buy)	231,336	-	-	Direct
Dec 12, 2025	TRAW Traws Pharma, Inc.	Award(A)	36,943	-	-	Direct
Oct 12, 2025	TRAW Traws Pharma, Inc.	Award(A) Stock Option (right to purchase)	64,839	-	-	Direct
Jun 13, 2025	IOVA IOVANCE BIOTHERAPEUTICS, INC.	Award(A) Deferred Restricted Stock Unit	135,092	-	-	Direct
Nov 1, 2024	No ticker Lomond Therapeutics Holdings, Inc.	Award(A) Stock Option (Right to Buy)	2,096,667	-	-	Direct

1-7 of 7 transactions

About Dukes Iain D.

Dukes Iain D. (SEC CIK 0001681955) files insider reports with the SEC as Chief Executive Officer of Traws Pharma, Inc. (TRAW), Director of IOVANCE BIOTHERAPEUTICS, INC. (IOVA) and CEO and Chairman of Lomond Therapeutics Holdings, Inc.

Signal8 holds 8 ownership filings by Dukes Iain D. (1 Form 3, 7 Form 4), filed between Nov 5, 2024 and Jul 14, 2026. Those filings report 7 transactions, from Nov 1, 2024 to Jul 9, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Dukes Iain D.'s filings is in NEWTOWN, PA.

Recent filings by Dukes Iain D.

Jul 9, 2026: Grant or award of TRAW derivative securities (Form 4, code A).
Jun 16, 2026: Grant or award of IOVA derivative securities (Form 4, code A).
Mar 8, 2026: Grant or award of TRAW derivative securities (Form 4, code A).
Dec 12, 2025: Grant or award of TRAW shares (Form 4, code A).
Oct 12, 2025: Grant or award of TRAW derivative securities (Form 4, code A).

Other insiders filing for Traws Pharma, Inc. (TRAW)

Pauza Charles David, Chief Science Officer Virology
CAUTREELS WERNER, Director
Savchuk Nikolay, Chief Operating Officer
STOVER JACK E, Director
Redfield Robert, Chief Medical Officer
Parker Charles Nolan, Chief Financial Officer

How to read Form 4 transaction codes